Final Program [International AIDS Society (11th: 1996: Vancouver, Canada)]

VENUE ROOM TRACK SESSION NO. TIME I SESSION PATHWAYS
P........

Bay 4
Exhibit
& Poster
Hall

412 Track B: Clinical Science
Poster Discussion:
Immunomodulators
Moderators:
J. Marriott, UK / Chris Tsoukas, Canada

Th.B. 170
AN EVALUATION OF THE SAFETY AND TOXICITIES OF THALIDOMIDE THERAPY IN HIV-I INFECTED INDIVIDUALS
Haslett, Patrick AJ,Tramontana JM, Burroughs M, Hempstead M, Kaplan G. The Rockefeller University New York, NY USA................................................................................................................................................................................................................................................
Th.B. 172
EFFECT OF MONTHLY TRANSFUSION OF HUMAN IVIG AND CROSS-MATCHED PERIPHERAL BLOOD MONONUCLEAR
CELLS IN LATE-STAGE AIDS PATIENTS
Gomatos Peter J, ReiterWM, Keller RH,Tomaka F, Giannetti B, Uribe MR. Center for Special Immunology, Ft. Lauderdale, FL, USA.
Th.B.173
CD8+ LYMPHOCYTE STIMULATION IN HIV-INFECTED PATIENTS
Ben Amar, Mohamed, Morisset R, Poirier G, Ghadirian P Research Center, H6teI-Dieu Hospital, University of Montreal, Montreal, QC,
Canada................................................................................................................................................................................................................................................
Th.B. 174
ABSENCE OF CLINICAL, IMMUNOLOGICAL AND VIROLOGICAL PROGRESSION AFTER 36 MONTHS IN HIV- I INFECTE
PATIENTS IMMUNIZED AGAINST ALPHA INTERFERON
GringeriAlessandro', Santagostino E', Cusini MI, Muca-Perja Mi, Gucciardo GI, Mannucci PMI, Hermans P2, Burny A3, ChamsV4,
Zagury JF4, Bizzini B4, Zagury D4. 'A. Bianchi Bonomi Hemophilia & Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore
Hospital & University of Milan, Milan, Italy; 2St. Pierre Hospital; 3Universite Libre de Bruxelles, Brussels, Belgium; 4Laboratoire de
Physiologie Cellulaire, Universite Pierre et Marie Curie, Paris, France................................................................................................................................................................................................................................................
Th.B. 175
PASSIVE IMMUNOTHERAPY IN ADVANCED HIV INFECTION AND THERAPEUTIC PLASMAPHERESIS IN ASYMPTOMATIC
HIV POSITIVE INDIVIDUALS
Blick, Gary', Scott WF2, Crook SW3, Buchanan SL3, Garton T3, Hopkins U3,Vadeboncceur AM3, Bulcraig IA2, Karpas A4. INY Medical
College,Valhalla, NY USA; 2Heriot-Watt University Edinburgh, UK; 3Southern New England Community Consortium, Greenwich, CT,
USA; 4University of Cambridge, Cambridge, UK. o
U
Th.B.176 >
A PLACEBO CONTROLLED PHASE II TRIAL OF THALIDOMIDE IN ASYMPTOMATIC HIV POSITIVE PATIENTS: CLINICAL
TOLERANCE AND EFFECT ON ACTIVATION MARKERS AND CYTOKINES
Marriott, JBI, Cookson SI, Carlin E2,Youle M2, Hawkins D2, Nelson M2, Pearson M2,Vaughan AI, Gazzard B2, Dalgleish A. ISt. George's c
Hospital Medical School; 2Kobler Centre, St. Stephen's Clinic, London, UK. o
a1)
u............................................................................................................................................................................................................................................... -
Th.B. 177
CLINICAL AND IMMUNOLOGICAL ASPECTS OF HIV-INFECTED PATIENTS IN DOUBLE BLIND TRIAL WITH VAXSYN~o
(rgp 160) AND AZT OR RELATED PLACEBO U
Guerra ECI,Varani ARI, Mezzaroma Ivano', Carlesimo MI, Ricci GI, Pinter E', Scala E', Antinori A2, Ammassari A2, De Luca A2, Murri
R2,Visconti E2,Vella S3, Ortona L2, Aiuti F'. IDept. Allergy/Clinical Immunology, University of Rome "La Sapienza"; 2lnstitute of Infectious
Diseases, Catholic University of Rome; 3National Institute of Health, Rome, Italy E
X
a--
x

239